MSB 0011359C

Drug Profile

MSB 0011359C

Alternative Names: M-7824; MSB0011359C

Latest Information Update: 14 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator EMD Serono
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action CD274 antigen inhibitors; Transforming growth factor beta modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 20 Oct 2017 National Cancer Institute plans a phase II trial of the combination of rilimogene galvacirepvec-rilimogene glafolivec, CV 301 and MSB 0011359C for Prostate cancer (Combination therapy) in USA (NCT03315871)
  • 02 Jun 2017 Additional safety, efficacy and pharmacokinetic data from a phase I trial in Solid tumours presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 01 Apr 2017 Pharmacodynamics data from a preclinical trial in Solid tumours presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top